Medical device commercialization is the work of turning a validated invention into a product that is cleared by the FDA, built under a quality system, paid for by payers and used by clinicians. In the United States it runs on four tracks at once: intellectual property, regulatory, reimbursement and funding. Teams that start all four early move faster than teams that finish a prototype first and ask the other questions later.
This guide is written for university researchers, technology transfer offices and founders. It walks through the stages, the choice between licensing and a startup, the FDA routes, the quality and clinical evidence you need, and the reimbursement question that decides whether a cleared device ever reaches patients.
TL;DR
- Commercialization covers market evaluation, design, verification and validation, regulatory submission, manufacturing transfer, reimbursement and launch. The tracks overlap, so plan them together.
- Decide early whether to license the technology to an established company or form a startup. Each fits a different kind of invention and team.
- The FDA risk class sets your route: 510(k) for most Class II devices, PMA for Class III, with De Novo and other options for novel or special cases.
- Start your coverage, coding and payment plan well before FDA clearance. Reimbursement is where many cleared devices stall.
- An outside advisory team with technology transfer, grant and industry experience can shorten the path from lab to launch.
Table of Contents
- What medical device commercialization involves
- Start with the clinical need and the market
- Protect the invention before you talk about it
- License the technology or form a startup
- Find the FDA pathway that fits your device
- Build the quality system and clinical evidence early
- Plan reimbursement before the FDA decision
- What a launch plan needs before you ship
- Fund the work in stages
- Our perspective on getting devices to market
- How Tech Transfer Advisors can help
- FAQ
- Sources
What medical device commercialization involves
A useful way to picture it is as a sequence with feedback loops. The BIO Medical Device Commercialization Primer lays out the development side as market evaluation, concept design, engineering, verification, validation and manufacturing transfer. The approval-to-market side follows with regulatory submission, scale-up, reimbursement, launch and post-launch assessment.
The stages in plain terms:
- Need and market evaluation. Is there an unmet clinical need, and is the market big enough to justify the cost of development?
- Protection and ownership. Who owns the invention, what can be patented, and can you practice it without infringing someone else?
- Design and engineering. Concept, prototype and design controls that are documented as you go.
- Verification and validation. Bench, animal and, where required, human testing.
- Regulatory authorization. The FDA pathway that matches the device's risk and novelty.
- Reimbursement and market access. Coverage, coding and payment.
- Manufacturing, launch and post-market duties. Scale-up, sales channels and ongoing FDA obligations.
None of these is a clean hand-off. A design choice made in stage three can change the regulatory class in stage five. A reimbursement gap found in stage six can force a new clinical study that should have been planned in stage four. That is why the best plans are drawn up backward from the launch.
Start with the clinical need and the market
Most failed devices do not fail on engineering. They fail because the problem was not painful enough, the buyer was unclear or the market was too small. The University of Minnesota's Medical Device Innovation Handbook recommends testing an idea against the unmet clinical need, how the solution differs from current practice, evidence from clinicians, whether it could become a new standard of care, and whether it may improve outcomes or lower costs.
The same handbook warns about a common pattern: novice innovators lean on claims of a huge market and billions in revenue, yet rarely back them with rigorous secondary research and an objective market size estimate. It also notes that investors tend to like innovations with the potential to generate over $100M per year. Whether or not your device targets that scale, the lesson holds. Build the market number from the bottom up: procedures performed, sites of care, who decides to buy, and what they pay today for the alternative.
A practical checklist for this stage:
- Interview clinicians who would actually use the device, not only the inventor's collaborators.
- Identify the economic buyer (hospital, ambulatory center, physician practice) and the person who holds the budget.
- Map the current standard of care and what it costs the system.
- Define a target product profile: indications, performance targets and the claims you will need to make.
If you want to go deeper on sizing, our guide to biotech market research shows how to size and validate a market before you commit capital.
Protect the invention before you talk about it
Intellectual property is the asset that makes everything else possible. The University of California's Entrepreneurs' Guide explains that the U.S. patent system provides a limited 20-year protection period, and that nearly all IP licenses to startup companies are exclusive, because exclusivity gives investors a reason to fund high-risk development. It also makes the underlying argument clearly: without the protection of a patent license, industry would not risk the money and time needed to develop products, and university discoveries could sit unused.
For device teams, this has practical consequences:
- File before public disclosure. Papers, posters and conference talks can damage patent rights.
- Confirm ownership. Inventions made with university resources or federal funding usually pass through the institution's technology transfer office. Our overview of how university tech transfer turns research into a product explains the usual flow.
- Check freedom to operate. Owning a patent does not mean you are free to sell. A freedom to operate analysis looks at other people's patents that your device might touch, and it is far cheaper to learn that before a financing than after.
- Plan the patent portfolio around the product. Device claims, method claims and improvements each play a different role in a license or a funding round.
License the technology or form a startup
This is the first big strategic fork. The Boston Children's Hospital Inventor's Guide describes a startup as a new business entity formed to commercialize one or more technologies, and as an alternative to licensing the IP to an established business. It lists the factors that should drive the choice: expected business viability, product development risk, the potential for multiple products from a platform technology, the startup's competitive advantage, the target market, potential revenues and the interest of the inventors.
The University of Connecticut's selection criteria for university startups add a useful screen. They look at novelty supported by initial data, market size, whether the technology can be protected, scalability, the return compared with a typical license, availability of a prototype or proof of concept, and a visible path to profitability. The same page stresses three ingredients for a successful startup: an idea supported by initial data, an experienced team and a business plan that works as a road map. It also reminds readers that not every great idea needs to be a company.
| Question | Points toward licensing | Points toward a startup |
|---|---|---|
| Scope of the technology | Improves an existing product line | Platform with several possible products |
| Development risk | Low to moderate, an industry partner can absorb it | High, needs focused team and dedicated capital |
| Inventor involvement | Inventors prefer to stay in the lab | Inventors want to lead or join the company |
| Market fit | An established company already sells to your buyer | New category or new buyer |
| Capital needed | Modest | Large, with investors and grants in play |
Neither route is better in general. The right choice depends on the invention, the team and the market. If you are unsure, a structured assessment of both options before you commit is the cheapest decision you will make. Our guide to life science commercialization covers how those decisions play out from the lab bench to market.
Find the FDA pathway that fits your device
The FDA's page on how to study and market your device lists the marketing pathways: Premarket Notification (510(k)), De Novo classification request, Exempt, Premarket Approval (PMA), Product Development Protocol, Humanitarian Device Exemption and Biologics License Application. Some Class I devices and most Class II devices require a 510(k), while Class III devices require a PMA.
The class reflects risk. According to the NIH SEED Regulatory Knowledge Guide for Therapeutic Devices, Class I devices pose little to no risk and typically do not need premarket authorization from CDRH, Class II devices pose moderate risk, and Class III devices pose the highest risk and face the most rigor in review.
How to think about it:
- A similar device is already on the market. A 510(k) is the usual route, and your task is to show your device is substantially equivalent to a legally marketed one.
- The device is novel but low to moderate risk. The De Novo route may fit. We cover eligibility, fees and timeline in our FDA De Novo guide.
- The device is high risk. Expect a PMA. NIH SEED's guidance on high-risk and novel devices says the process formally begins with a filing review. The FDA decides within 45 days whether to file the application or refuse to file it. From the filing date, the agency has 180 days to review the information and reach a decision.
Those are the statutory clocks, not a forecast of your calendar. Questions, additional information requests and the time it takes you to answer them are on top. For the full picture of strategy and sequencing, read our medical device regulatory strategy guide, and if you are weighing outside help, see what FDA regulatory consulting covers.
Build the quality system and clinical evidence early
Two requirements catch academic teams off guard: the quality system and the evidence plan.
Quality system and design controls
The NIH SEED regulatory guide explains that the quality system regulation specifies processes for design and manufacturing that device manufacturers must follow if their products are sold in the U.S. These cover design, purchasing, traceability, production, acceptance criteria, corrective and preventive actions (CAPA), packaging, handling, training and documentation. It also notes that design controls are part of cGMP requirements under the Safe Medical Devices Act.
The practical point: design controls are easiest when they are started during development. Retrofitting design history documents after a prototype is built is slow and often exposes gaps that require repeating tests. Even a lean team can keep a design history file, a risk analysis and traceable requirements from the first working prototype.
Clinical evidence
Not every device needs human testing. The NIH SEED guide says medical devices may or may not require it, and when they do, innovators should coordinate with their local institutional review board to evaluate safety and ethics. For studies of significant-risk devices, an Investigational Device Exemption sets the boundaries for introducing an investigational device into interstate commerce for research. An ACRP article on device research notes that the IDE regulation sits in 21 CFR Part 812 and that ICH E6 Good Clinical Practice is recognized in the U.S. as a standard for human subjects research.

The BIO primer lists choosing the appropriate level of clinical trial based on patient risk as a core learning objective for a reason. Over-building a study wastes capital, and under-building it can leave you with data that satisfies neither the FDA nor payers. Design the study with both audiences in mind.
Plan reimbursement before the FDA decision
Clearance lets you sell a device. Reimbursement determines whether anyone can afford to buy it. The NIH SEED Reimbursement Knowledge Guide states that a strategy for coverage, coding and payment should begin early, well in advance of FDA clearance or approval.
The guide describes the foundation as research: define the device type, establish a plan for regulatory approval, formulate a target product profile, evaluate competitors, collect evidence, identify potential providers and payers, and determine the target patient population.
The delay between clearance and coverage can be long. Medical Design and Outsourcing reported in February 2026 on data from Stanford Biodesign showing that the average time for breakthrough medical technology to go from FDA clearance or approval to even nominal coverage in the U.S. is 5.7 years. The report quotes Josh Makower cautioning that this span could strain the venture capital model, since funds typically have a life of about 10 years.
What that means for your plan:
- Ask in the earliest clinical conversations how the procedure is billed today and which codes might apply.
- Treat payer evidence as a design input. The outcome measures that persuade a payer may not be the ones the FDA needs.
- Budget runway for the gap between clearance and revenue. Investors will ask.
- Identify early adopters who can use the device in settings where reimbursement is less of a barrier.
What a launch plan needs before you ship
The Definitive Healthcare launch guide says market access and reimbursement strategy can take five to seven years to develop, so planning should start well before an FDA submission. Its launch checklist is a good template:
- Identify the relevant payors and understand their approval processes.
- Investigate code development.
- Finalize design transfer to manufacturing under 21 CFR Part 820.
- Set up an order management system.
- Align with market access, health economics and medical affairs on the evidence needed for reimbursement.
After authorization the obligations continue. For a PMA device, the NIH SEED guidance explains that manufacturers must register, list, pay fees and submit a detailed annual report documenting every change to manufacturing or labeling, along with related findings in the scientific literature. Substantial updates need a PMA supplement. Build the staff, systems and budget for post-market compliance into the company plan from the start, not as an afterthought.
Fund the work in stages
Device development is expensive, and the money arrives in tranches tied to milestones: proof of concept, design freeze, a clinical readout, clearance. Match each source of capital to the milestone it can realistically fund. Non-dilutive options such as SBIR and STTR grants can carry early validation without giving up equity, while investors typically come in once technical and market risk are visibly lower. Our guide to startup funding strategy shows how to line up capital with milestones so you are not raising on a deadline.
Our perspective on getting devices to market
We have sat on many sides of this table: inside major university technology transfer offices, in startup leadership, on federal grant review panels and in industry commercialization. Across those seats, one pattern repeats. Good inventions stall not because the science is weak but because the commercial questions were asked in the wrong order.
Our view is that a device should be treated as a business case from the first disclosure. Before a dollar goes into prototypes, we want a clear answer on the clinical need, the buyer, the patent position and the likely FDA route. That discipline saves researchers from building something nobody can pay for, and it gives institutions a defensible basis for choosing between a license and a spinout.
We also believe in integrated support. Strategy, IP and legal work should talk to one another. That is why we coordinate legal matters with a dedicated IP law partner, so a licensing structure or a patent decision is not made in isolation from the commercial plan.
With a combined experience of more than 50 years in tech transfer, we aim to give universities, researchers and founders a tailored plan, introductions to investors and industry, and a funding strategy that includes SBIR and STTR grants where they fit. Our goal is simple: raise the odds that good research becomes a product patients can actually get.
the author
How Tech Transfer Advisors can help
We work with universities, researchers, founders and companies on the commercial side of medical devices: IP and patent strategy, licensing structure, spinout formation, go-to-market planning, investor introductions, funding strategy and market assessments. Our team's background includes university technology transfer offices, startup leadership, federal grant review and industry commercialization.

If you have a device invention and are weighing a license against a startup, or need a market and regulatory reality check before you invest, see our consulting services or reach out through Tech Transfer Advisors. Engagements are tailored to the project, whether that means a defined scope or ongoing advisory support.
FAQ
How long does medical device commercialization take?
There is no single number, because it depends on device class, the evidence required and the reimbursement picture. The FDA's statutory PMA review clock is 180 days from filing, but development, testing and the response to FDA questions come before and during it. Coverage can take much longer than clearance, so plan the timeline around payment, not only authorization.
Should a researcher license a device or start a company?
It depends on the technology and the people. Licensing suits improvements that an established company can absorb. A startup fits platforms with several potential products, high development risk that needs a focused team, and inventors who want to lead. Compare viability, risk, competitive advantage, target market and inventor interest before deciding.
Which FDA pathway will my device need?
It depends on risk class and whether a similar legally marketed device exists. Some Class I and most Class II devices need a 510(k), Class III devices need a PMA, and novel lower-risk devices may qualify for De Novo classification. The FDA's device advice pages are the place to confirm the route for your specific product.
When should I think about reimbursement?
As early as the concept stage. NIH SEED guidance says the coverage, coding and payment strategy should begin well before FDA clearance or approval. Early work on payers, codes and evidence prevents a cleared device from waiting years for coverage.
Do I need clinical trials?
Not always. Some devices need human testing and others do not. When testing is required, coordinate with your institutional review board, and for significant-risk devices expect an Investigational Device Exemption. Choose the study level based on patient risk and on what both the FDA and payers will need to see.
Sources
- Medical Device Commercialization Primer, BIO
- Evaluating Your Medical Device Idea, University of Minnesota
- Entrepreneurs' Guide, University of California
- Inventor's Guide, Boston Children's Hospital
- Selection Criteria, UConn Technology Commercialization Services
- How to Study and Market Your Device, FDA
- Regulatory Knowledge Guide for Therapeutic Devices, NIH SEED
- FDA Authorization for High-Risk or Novel Devices, NIH SEED
- Regulatory and Development Approaches to Research for In Vitro Diagnostics, ACRP
- Reimbursement Knowledge Guide for Medical Devices, NIH SEED
- Josh Makower warns of the biggest challenge to medtech innovation, Medical Design and Outsourcing
- Launching your medical device: a strategy and execution guide, Definitive Healthcare
